CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
被引:356
作者:
French, RR
论文数: 0引用数: 0
h-index: 0
机构:
Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, EnglandGen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England
French, RR
[1
]
Chan, HTC
论文数: 0引用数: 0
h-index: 0
机构:
Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, EnglandGen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England
Chan, HTC
[1
]
Tutt, AL
论文数: 0引用数: 0
h-index: 0
机构:
Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, EnglandGen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England
Tutt, AL
[1
]
Glennie, MJ
论文数: 0引用数: 0
h-index: 0
机构:
Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, EnglandGen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England
Glennie, MJ
[1
]
机构:
[1] Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England
CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8(+) T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40(+) lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40(-) lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8(+) T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Bennett, SRM
Carbone, FR
论文数: 0引用数: 0
h-index: 0
机构:
PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, AustraliaPO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Carbone, FR
Karamalis, F
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Karamalis, F
Flavell, RA
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Flavell, RA
Miller, JFAP
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Miller, JFAP
Heath, WR
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Bennett, SRM
Carbone, FR
论文数: 0引用数: 0
h-index: 0
机构:
PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, AustraliaPO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Carbone, FR
Karamalis, F
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Karamalis, F
Flavell, RA
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Flavell, RA
Miller, JFAP
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia
Miller, JFAP
Heath, WR
论文数: 0引用数: 0
h-index: 0
机构:PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia